{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The Evaluation of Liraglutide 3.0 mg in Patients With Poor Weight Loss and a Suboptimal Glucagon-Like Peptide-1 Response (BARI-OPTIMISE) randomized placebo-controlled trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomized placebo-controlled trial recruited adult patients at least 1 year after metabolic surgery who had experienced 20% or less body weight loss from the day of surgery and a suboptimal nutrient-stimulated GLP-1 response from 2 hospitals in London, United Kingdom, between October 2018 and November 2019."
      },
      "Participants": {
        "score": 2,
        "evidence": "recruited adult patients at least 1 year after metabolic surgery who had experienced 20% or less body weight loss from the day of surgery and a suboptimal nutrient-stimulated GLP-1 response from 2 hospitals in London, United Kingdom"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Liraglutide, 3.0 mg, once daily or placebo as an adjunct to lifestyle intervention with a 500-kcal daily energy deficit for 24 weeks"
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the efficacy and safety of the GLP-1 receptor agonist, liraglutide, 3.0 mg, on percentage body weight reduction in patients with poor weight loss and suboptimal GLP-1 response after metabolic surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was change in percentage body weight from baseline to the end of the 24-week study period based on an intention-to-treat analysis."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "on a 1:1 allocation by computer-generated randomization sequence, stratified by surgery type (Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [SG]) and type 2 diabetes status."
      },
      "Blinding": {
        "score": 3,
        "evidence": "All participants and clinical study personnel were blinded to treatment allocation."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 70 participants (mean [SD] age, 47.6 [10.7] years; 52 [74%] female) with a poor weight loss response following RYGB or SG were randomized to receive 3.0-mg liraglutide (n\u2009=\u200935) or placebo (n\u2009=\u200935)."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Estimated change in mean (SD) percentage body weight from baseline to week 24 was \u22128.82 (4.94) with liraglutide, 3.0 mg (n\u2009=\u200931), vs \u22120.54 (3.32) with placebo (n\u2009=\u200926)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The mean difference in percentage body weight change for liraglutide, 3.0 mg, vs placebo was \u22128.03 (95% CI, \u221210.39 to \u22125.66; P <\u2009.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events, predominantly gastrointestinal, were more frequent with liraglutide, 3.0 mg (28 events [80%]), than placebo (20 events [57%])."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT03341429"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}